Insider Transactions Reported by 30 Insiders of
OnKure Therapeutics, Inc.
-
Symbol
-
OKUR on Nasdaq
-
Location
-
Boulder, CO
Quick Takeaways
- OKUR - OnKure Therapeutics, Inc. has 30 insiders with reported activity on this page.
- Net insider value flow over the last year: -$832,283.
- Recent transaction rows are available for direct filing-level review.
What Changed
- Buy value: $2,590,000; sell value: $3,422,282.
- Net share flow: <span class="text-red-600">-441,657</span>.
Why This Matters
- This page gives a plain-language issuer insider context before you inspect transaction-level evidence.
- Use the filing links below to verify timestamps, codes, and ownership impacts directly from SEC forms.
Official SEC Source
Filed on Form 4
Issuer insider activity is sourced from SEC Forms 3, 4, and 5.
See Original Filing
Insiders trading volume in the past year
Insider trading buckets (0-12 months)
OnKure Therapeutics, Inc. executives and other stock owners filed with the SEC include:
| Name |
Relationship |
Holdings Value |
Past Year Net Change |
Change % |
Valuation |
Report Date |
| Novo Holdings A/S |
10%+ Owner |
$20,900,196 |
|
|
Mixed |
23 Jun 2023 |
| ACORN BIOVENTURES, L.P. |
10%+ Owner |
$9,098,765 |
+$2,590,000 |
+40% |
Mixed |
15 May 2025 |
| ACORN BIOVENTURES 2, L.P. |
10%+ Owner |
$2,869,514 |
|
|
Mixed |
15 May 2025 |
| Gregory J. Flesher |
President and CEO, Director |
$722,961 |
|
|
Mixed |
09 Dec 2022 |
| Braden M. Leonard |
Former 10% owner of RPHM |
$670,111 |
|
|
Mixed |
07 Oct 2024 |
| Michael Cruse |
Chief Operating Officer |
$310,364 |
|
|
Mixed |
09 Dec 2022 |
| Ashley Hall |
Chief Development Officer |
$248,518 |
|
|
Filing P/S |
28 Aug 2023 |
| Vineet R. Jindal |
Chief Financial Officer |
$229,691 |
|
|
Mixed |
10 Dec 2021 |
| Alejandro Dorenbaum |
Chief Medical Officer |
$188,271 |
|
|
Mixed |
09 Dec 2022 |
| Jennifer P. Lam |
VP of Finance & Administration |
$129,279 |
|
|
Mixed |
09 Dec 2022 |
| Jason A. Leverone |
Chief Financial Officer |
$66,504 |
-$8,590 |
-11% |
Filing P/S |
01 Apr 2026 |
| Isaac Manke |
Director |
$61,749 |
|
|
Mixed |
31 Dec 2025 |
| Mathers Edward T. |
Director |
$45,930 |
|
|
Mixed |
31 Dec 2025 |
| Nicholas A. Saccomano |
President and CEO, Director |
$30,479 |
-$2,435 |
-7.4% |
Filing P/S |
01 Apr 2026 |
| R. Michael Carruthers |
Director |
$13,192 |
|
|
Mixed |
28 May 2025 |
| Cormorant Asset Management, LP |
Former 10% Owner |
$0 |
-$3,411,258 |
-100% |
Mixed |
15 May 2025 |
| Dylan Hartley |
Chief Scientific Officer |
|
|
|
Mixed |
01 Apr 2026 |
| Andrew John Phillips |
Director |
|
|
|
Mixed |
28 May 2025 |
| Valerie Malyvanh Jansen |
Director |
|
|
|
Mixed |
28 May 2025 |
| Samuel Agresta |
Chief Medical Officer |
|
|
|
Mixed |
01 Apr 2026 |
| Michael G. Grey |
Director |
|
|
|
Mixed |
28 May 2025 |
| Liam Ratcliffe |
Director |
|
|
|
Mixed |
31 Mar 2026 |
| Stacey Denenberg Seltzer |
Director |
|
|
|
Mixed |
06 Jun 2023 |
| Kenneth Ph.D. Harrison |
Director |
|
|
|
Mixed |
08 Apr 2021 |
| Niall O'Donnell |
Director |
|
|
|
Mixed |
06 Jun 2023 |
| Eric M. Dube |
Director |
|
|
|
Mixed |
06 Jun 2023 |
| Bali Muralidhar |
Director |
|
|
|
Mixed |
06 Jun 2023 |
| Paul W. Hoelscher |
Director |
|
|
|
Mixed |
06 Jun 2023 |
| Wendy S. Johnson |
Chief Development Officer |
|
|
|
Mixed |
14 Jul 2021 |
| Roshawn A. Blunt |
Director |
|
|
|
Mixed |
06 Jun 2023 |
Recent Insider Transactions by Companies or Individuals for OnKure Therapeutics, Inc.
Showing up to 300 most recent insider transactions from the last 12 months.
| Insider |
Symbol |
Class |
Transaction |
% |
Value $ |
* Price $ |
Shares |
Shares Owned |
Date |
Ownership |
| Nicholas A. Saccomano |
OKUR |
Employee Stock Option (right to buy) |
Award |
|
|
|
330,000 |
330,000 |
01 Apr 2026 |
Direct |
| Jason A. Leverone |
OKUR |
Employee Stock Option (right to buy) |
Award |
|
|
|
110,000 |
110,000 |
01 Apr 2026 |
Direct |
| Dylan Hartley |
OKUR |
Employee Stock Option (right to buy) |
Award |
|
|
|
110,000 |
110,000 |
01 Apr 2026 |
Direct |
| Samuel Agresta |
OKUR |
Employee Stock Option (right to buy) |
Award |
|
|
|
110,000 |
110,000 |
01 Apr 2026 |
Direct |
| Liam Ratcliffe |
OKUR |
Stock Option (right to buy) |
Award |
|
|
|
15,300 |
15,300 |
31 Mar 2026 |
Direct |
| Nicholas A. Saccomano |
OKUR |
Class A Common Stock |
Sale |
-1.16% |
$357 |
$4.16 |
-86 |
7,333 |
23 Mar 2026 |
Direct |
| Jason A. Leverone |
OKUR |
Class A Common Stock |
Sale |
-1.85% |
$1,251 |
$4.16 |
-301 |
16,000 |
23 Mar 2026 |
Direct |
| Mathers Edward T. |
OKUR |
Class A Common Stock |
Award |
34.3% |
|
|
3,911 |
15,310 |
31 Dec 2025 |
Direct |
| Isaac Manke |
OKUR |
Class A Common Stock |
Award |
34.3% |
|
|
5,258 |
20,583 |
31 Dec 2025 |
Direct |
| Nicholas A. Saccomano |
OKUR |
Class A Common Stock |
Sale |
-1.16% |
$258 |
$2.97 |
-87 |
7,419 |
22 Dec 2025 |
Direct |
| Jason A. Leverone |
OKUR |
Class A Common Stock |
Sale |
-1.82% |
$896 |
$2.97 |
-302 |
16,301 |
22 Dec 2025 |
Direct |
| Mathers Edward T. |
OKUR |
Class A Common Stock |
Award |
56.7% |
|
|
4,125 |
11,399 |
30 Sep 2025 |
Direct |
| Isaac Manke |
OKUR |
Class A Common Stock |
Award |
56.7% |
|
|
5,545 |
15,325 |
30 Sep 2025 |
Direct |
| Nicholas A. Saccomano |
OKUR |
Class A Common Stock |
Sale |
-2.45% |
$231 |
$2.62 |
-88 |
3,506 |
22 Sep 2025 |
Direct |
| Jason A. Leverone |
OKUR |
Class A Common Stock |
Sale |
-2.35% |
$795 |
$2.62 |
-303 |
12,603 |
22 Sep 2025 |
Direct |
| Mathers Edward T. |
OKUR |
Class A Common Stock |
Award |
181.9% |
|
|
4,694 |
7,274 |
30 Jun 2025 |
Direct |
| Isaac Manke |
OKUR |
Class A Common Stock |
Award |
181.9% |
|
|
6,311 |
9,780 |
30 Jun 2025 |
Direct |
| Nicholas A. Saccomano |
OKUR |
Class A Common Stock |
Sale |
-2.39% |
$210 |
$2.38 |
-88 |
3,594 |
23 Jun 2025 |
Direct |
| Jason A. Leverone |
OKUR |
Class A Common Stock |
Sale |
-2.29% |
$722 |
$2.38 |
-303 |
12,906 |
23 Jun 2025 |
Direct |
| Mathers Edward T. |
OKUR |
Stock Option (right to buy) |
Award |
|
|
|
7,650 |
7,650 |
28 May 2025 |
Direct |
| Andrew John Phillips |
OKUR |
Stock Option (right to buy) |
Award |
|
|
|
7,650 |
7,650 |
28 May 2025 |
Direct |
| Isaac Manke |
OKUR |
Stock Option (right to buy) |
Award |
|
|
|
7,650 |
7,650 |
28 May 2025 |
Direct |
| Valerie Malyvanh Jansen |
OKUR |
Stock Option (right to buy) |
Award |
|
|
|
7,650 |
7,650 |
28 May 2025 |
Direct |
| Michael G. Grey |
OKUR |
Stock Option (right to buy) |
Award |
|
|
|
7,650 |
7,650 |
28 May 2025 |
Direct |
| R. Michael Carruthers |
OKUR |
Stock Option (right to buy) |
Award |
|
|
|
7,650 |
7,650 |
28 May 2025 |
Direct |
| Cormorant Asset Management, LP |
OKUR |
Class A Common Stock |
Sale |
-100% |
$3,363,023 |
$1.85 |
-1,813,439 |
0 |
15 May 2025 |
See Footnote |
| ACORN BIOVENTURES, L.P. |
OKUR |
Common Stock |
Purchase |
|
$2,090,000 |
$1.85 |
1,129,730 |
1,129,730 |
15 May 2025 |
By Acorn Bioventures 2, L.P. |
| ACORN BIOVENTURES, L.P. |
OKUR |
Common Stock |
Purchase |
18.8% |
$500,000 |
$1.85 |
270,270 |
1,709,944 |
15 May 2025 |
Direct |
| Cormorant Asset Management, LP |
OKUR |
Class A Common Stock |
Sale |
-1.32% |
$48,236 |
$1.98 |
-24,300 |
1,813,439 |
12 May 2025 |
See Footnotes |
| Nicholas A. Saccomano |
OKUR |
Class A Common Stock |
Sale |
-12.3% |
$1,378 |
$2.67 |
-516 |
3,682 |
07 Apr 2025 |
Direct |
| Jason A. Leverone |
OKUR |
Class A Common Stock |
Sale |
-12.2% |
$4,925 |
$2.67 |
-1,844 |
13,209 |
07 Apr 2025 |
Direct |
* An asterisk sign (*) next to the price indicates that the price is likely invalid.